Abstract: An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.
Type:
Grant
Filed:
March 7, 2017
Date of Patent:
April 25, 2023
Assignees:
NATIONAL CANCER CENTER JAPAN, RIN INSTITUTE INC.
Abstract: Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.
Type:
Grant
Filed:
February 5, 2018
Date of Patent:
March 14, 2023
Assignees:
National Cancer Center Japan, Kyoto University, Takeda Pharmaceutical Company Limited
Abstract: A method for producing a professional antigen-presenting cell, including inducing expression of c-MYC, BMI1, and MDM2 in a myeloid cell (MC) to obtain a proliferative myeloid cell (pMC), and inducing expression of GM-CSF and/or M-CSF in the pMC to obtain a professional antigen-presenting cell (pAPC). The myeloid cell is a myeloid cell differentiated from a pluripotent stem cell.
Type:
Application
Filed:
November 10, 2022
Publication date:
March 9, 2023
Applicants:
AGC INC., National Cancer Center Japan
Abstract: The present invention provides an antibody beneficial for treatment of a solid tumor, an antibody-drug conjugate thereof, and an anticancer agent comprising these. The present invention provides, for example, an antibody that binds to tissue factor or an antigen-binding fragment thereof, wherein the antibody has a dissociation rate constant kd of 5×10?4 s?1 or more and an association rate constant Ka of 1×104 M?1 s?1 or more.
Type:
Grant
Filed:
October 29, 2018
Date of Patent:
July 5, 2022
Assignees:
National Cancer Center Japan, RIN Institute Inc.
Abstract: The present invention relates to an antibody-drug conjugate (ADC) and a composition containing the conjugate for use in treating cancer. According to the present invention, provided are an ADC of an antibody specific to insoluble fibrin and a drug in which a linker linking the antibody and the drug has a plasmin cleavage sequence, and a pharmaceutical composition containing the ADC for use in treating cancer.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
April 26, 2022
Assignees:
NATIONAL CANCER CENTER JAPAN, RIN INSTITUTE INC.
Abstract: [Problem] The present invention provides an antibody that binds to TMEM132A, an anticancer agent and a cancer test method. [Solution] An antibody that binds to TMEM132A.
Type:
Grant
Filed:
August 14, 2017
Date of Patent:
December 7, 2021
Assignees:
NATIONAL CANCER CENTER JAPAN, RIN INSTITUTE INC.
Abstract: The present invention provides an antibody beneficial for treatment of a solid tumor, an antibody-drug conjugate thereof, and an anticancer agent comprising these. The present invention provides, for example, an antibody that binds to tissue factor or an antigen-binding fragment thereof, wherein the antibody has a dissociation rate constant kd of 5×10?4 s?1 or more and an association rate constant Ka of 1×104 M?1s?1 or more.
Type:
Application
Filed:
October 29, 2018
Publication date:
July 22, 2021
Applicants:
National Cancer Center Japan, RIN Institute Inc.
Abstract: The present invention provides a method for producing hepatic stem/progenitor cells from mammal hepatocytes, comprising bringing a TGF?-receptor inhibitor, and optionally a GSK3 inhibitor and/or a ROCK inhibitor into contact with the hepatocytes in vitro.
Type:
Application
Filed:
January 6, 2017
Publication date:
January 10, 2019
Applicants:
National Cancer Center Japan, Cynity Co., Ltd.